Sunnybrook Health Sciences Centre

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).

Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

February 15, 2011
Susanne Staer
Media Coverage

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it – part of a growing trend of selling science to help shore up Canada’s troubled health-care system.

Tuesday’s agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question.

But the licensing deal with one of the world’s biggest drug companies is also savvy medically. Until recently, some hospitals were reticent to capitalize on their discoveries, seeing commercialization as unsavoury, but now many believe it’s one of the quickest ways to get a drug to their patients.

MaRS Innovation brokers deal between sanofi-aventis and Sunnybrook Health Sciences Centre

February 15, 2011
Susanne Staer
Industry Partners

Bridgewater, NJ and Toronto, ON- February 15, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research…

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements to collaboratively commercialize a novel therapeutic technology and three advances in medical imaging. These four technologies will impact diagnosis and care for epidemic chronic illnesses and have clear and broad commercial potential. MI will shepherd these opportunities through the next stages of the commercialization process.

Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“We are coming out of the gate vigorously in identifying this group of Sunnybrook technologies as commercialization opportunities,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MI. “MaRS Innovation sits with academic institutions at the hub of a major North American cluster in medical devices and biomedical engineering. This agreement will enable MaRS Innovation to leverage our resources with Sunnybrook’s and generate attractive investment packages.”

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

MaRS Innovation brokers deal between sanofi-aventis and Sunnybrook Health Sciences Centre

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

Quick Links

Contact Us